Methods: Thyroid imaging was performed on 21 euthyroid females and 16 hyperthyroid females,30 minutes after an intravenous injection of 10mCi (superscript 99m)Tc-tetrofosmin. The ratios of the 30-minute (superscript 99m)Tc-tetrofosmin thyroid uptake were calculated. Results:(A)the ratio of the 30-minute (superscript 99m)Tc-tetrofosmin thyroid uptake has positive relationship with the ratio of the 24-hr 131I thyroid uptake, although the correlation was not very good(R=0.589),and(B)the females with hyperthyroidism had significantly higher ratios of the 30-minute (superscript 99m)Tc-tetrofosmin thyroid uptake than those with euthyroidism(4.07±SEM 0.49vs.2.42±SEM 0.10,P<0.005).Conclusion: The 30-minute (superscript 99m)Tc-tetrofosmin thyroid uptake ratio may have potential to diagnose hyperthyroidism.
Backgrounds: The purpose of this preliminary study was to compare planar and single photon emission computed tomography(SPECT)techniques to detect acute myocardial infarction(AMI)using newly developed gamma camera. Material and Methods: Our study included 8 acute coronary artery syndrome patients with clinical suspicion of AMI. All patients had both planar and SPECT (superscript 99m)Tc-PYP cardiac scintigraphies using vertical dual head gamma camera. Each set of images was interpreted in random order by three experienced and ”blinded” observers who had no knowledge of relevant clinical or laboratory data. At least two positive readings of each imaging set from the three observers was considered as positive. All planar image sets were graded on a scale of 0 to 4+ modified from Poliner LR et al.(Circulation 1979;59:257-267).The color scales of all SPECT images were re-normalized base on the peak voxel value of a normal thoracic spine and graded on a scale of 0 to 4+.Each grade of 2+ or greater was considered as positive in both planar and SPECT imaging. The relative portion of the total left ventricular myocardium involved was evaluated subjectively and compared to the territory related to the infarct coronary artery obtained by coronary angiography in both planar and SPECT studies. Results: The final diagnosis and the territory related to the infarct coronary artery had better correlation with the SPECT imaging than with the planar imaging(P<0.05).The additional scanning time for SPECT imaging was less than 5 minutes as compared with that for the planar imaging when using vertical dual head gamma camera(10vs.5.5±0.4 minutes).Conclusion: Due to better correlation in both sensitivity and lesion detection for AMI in SPECT imaging than in planar imaging and worldwide population use of SPECT technique, we thus suggest (superscript 99m)Tc-PYP SPECT imaging instead of (superscript 99m)Tc-PYP planar imaging to detect patients who had clinically suspicious AMI.
前言:巴金森氏病是一種進行性神經退化性異常,以選擇性基底核及黑質組織多巴胺流失為特徵。本研究在評估鎝-99m-TRODAT-1對巴金森氏病異常多巴胺轉運器活性之偵測潜力。方法:巴金森氏病台灣獼猴(Macaca cyclopis)是在磁振攝影指引下將6-羟基多巴胺注入猴子前腦內側束以破壞紋狀體內之多巴胺神經,並以健康猴子作為對照組。病態組則以猴出現巴金森氏症行為及氟-18氟化多巴正子造影評估其嚴重度。鎝-99m-TRODAT-1由凍晶小瓶加入鎝-99m-過鎝酸鈉生理鹽水製備成。靜脈注射740 MBq鎝-99m-TRODAT-1後30分鐘進行頭部動態造影,續以雙頭Helix造影儀配置Fan-Beam準直儀,進行腦部單光子射出斷層造影至4小時。結果:動態造影可見腦部有放射活性增加現象。單光子射出斷層造影則在正常猴子的紋狀體有明顯活性攝取,而病態猴子則在該部位出现明顯活性減弱現象。紋狀體/腦及紋狀體/小腦比率在注射後90-120分鐘分別為1.7及2.1(病態猴)以及3.2及3.3(正常猴)。值得注意的是:病態猴紋狀體之殼部活性下降程度比尾狀核明顯。整個造影過程及造影之後,猴子並未出現不良副作用。結論:台灣獼猴可作為鎝-99m-TRODAT-1腦部研究的動物模式。此外,鎝-99m-TRODAT-1可能成為評估巴金森氏病多巴胺轉運器變化的有效方法。
前言:鎝-99m-HMPAO爲核醫腦血流造影診斷的重要核醫藥物,由於鎝-99m-HMPAO的不安定性限制本藥必須在標幟後三十分鐘內使用。本研究目的為評估次甲藍-磷酸鈉及氯化亞鈷溶液對核研所HMPAO凍晶小瓶製備之鉻-99m-HMPAO之穩定效果,並與英國Amersham公司Ceretec kit比較。材料與方法:本研究共使用三十隻紐西蘭公兔並分為五組,第一組注射未添加穩定劑的鎝-99m-HMPAO。第二組注射添加次甲藍-磷酸鈉溶液的鎝-99m-HMPAO,並於標幟後十分鐘注射。第三組注射添加氯化亞鈷水溶液的鎝-99m-HMPAO,並於標幟後十分鐘注射。第四組注射添加次甲藍-磷酸鈉溶液的鎝-99m-HMPAO,並於標幟後四小時注射。第五組注射添加氯化亞鈷水溶液的鎝-99m-HMPAO,並於標幟後四小時注射。各組並分為二小組,分別使用核研所產製之核研宏寶鎝及英國Amersham公司Ceretec凍晶小瓶製備之鎝-99m-HMPAO。每隻動物於注射後30、60、120、180、300分鐘分別進行核子醫學全身造影並以電腦計算出腦部攝取活性佔全身攝取活性之比率。結果:不論核研宏寶鎝或Amersham之Ceretec kit製備之鎝-99m-HMPAO加入次甲藍-磷酸鈉或氯化亞鈷溶液穩定劑均不會改變鎝-99m-HMPAO原來的放射化學純度,但會顯著延緩鎝-99m-HMPAO的分解;標幟6小時放射化學純度仍可維持在80%以上。比較次甲藍-磷酸鈉及氯化亞鈷溶液兩種穩定劑對搭-99m-HMPAO之放射化學穩定效果,並無明顯差異。加入次甲藍-磷酸鈉溶液或氯化亞鈷水溶液穩定劑,初期的大白兔腦部活性分佈以至後續的緩慢清除,與未添加穩定劑者沒有明顯差別,證實穩定劑的添加不會改變鎝-99m-HMPAO在腦組織之正常動態分佈。添加穩定劑4小時後注射之大白兔腦組織之正常動態分佈與標幟後10分鐘靜脈注射者差異有限。結論:研究結果顯示由核研所及Amersham生產之HMPAO凍晶小瓶製備之鎝-99m-HMPAO添加穩定劑(次甲藍或氯化亞鈷)後,均能延長臨床造影使用之放射化學穩定性達6小時,將可大幅提昇核醫臨床使用之方便性。
前言:[氟-18]去氧葡萄糖是正電子斷層攝影中最常用的核醫藥物之一,其代謝路徑終點為膀胱,而膀胱是所有器官當中累積最高劑量者。本研究之目的即是發展一精確的動態膀胱假體,使之能有效地評估膀胱劑量累積情形,供臨床給藥時之參考。材料與方法:本研究之膀胱假體是針對人體膀胱的生理特性而設計,假體內部以水塡充,将表面貼有TLD的氣球置入假體內,再以不同流速將適當濃度的18F-FDG徐徐注入。該假體可同時評估影響膀胱吸收劑量之各項因子,主要為:尿液活性濃度、尿液產生速率、排尿次數與時間、注射藥物前起始尿液的體積、殘餘尿液體積等。本研究也利用加馬光子劑量轉换的觀念,發展出計算膀胱吸收劑量之數學計算模式,此模式可方便地運用於臨床計算上。結果與討論:本研究採用熱發光劑量計來評估膀胱吸收劑量情形,證明為一可行的方法。經由數學計算模式所求得之膀胱吸收劑量,與實際所量測之結果加以比較,發現偏差皆在5%之滿意度內。本計算模式所具有之吸收劑量預測功能,對臨床評估十分方便。結論:雖然本動態膀胱假體能有效評估吸收劑量,惟仍無法有效模擬人體膀胱動態變化情形。為克服不同核醫藥物在體內有不同代謝分佈問題,本研究將在未來利用正電子斷層影像的資訊,取得膀胱內尿液活性與時間的關係,進而運用本劑量模式,發展一套可供臨床應用計算的方法。因為本研究建立在膀胱假體的基礎上,對於具有相同核種之核醫藥物,本劑量計算模式應可一併適用。
本病例報告一名45歲男性罹患甲狀腺體質癌,手術前後以201TI掃描連續追踪的重要性。在一系列4次的201TI掃描中清楚的顯示出術前病灶的範圍與位置,術後病灶的殘餘組織,及在接受sandostatin和放射治療後的病灶復發等。文中並討論201TI掃描在甲狀腺髓質癌術後立即偵測殘餘腫瘤組織及其他角色之應用。
一位42歲女性胃癌術後復發患者,因同時合併大量腹水及左側惡性肋膜腔積水住院治療。臨床上考慮以肋膜粘連術來治療惡性肋膜腔積水,在置放胸引流管後,懷疑患者有腹胸膜腔交通的可能,因此安排腹膜閃爍造影檢查。由於同位素隨著肋膜腔積水被移入引流器中,因此同位素顯影於胸引流管及引流器中,胸膜腔的掃描反而未能有造影出現。本文是在提醒臨床醫師,即使胸腔的掃描未能呈現典型的同位素聚集,並不能完全排除沒有腹胸膜腔交通的情形,我們必須將胸引流管及引流器列入掃描的範圍,也許可以證實腹胸膜腔交通的診斷,以避免偽陰性掃描的發生。
一位七十歲的男性前列腺癌病患,接受全身骨骼掃描以評估是否有骨轉移。因意外將99mTc-MDP注入左手肘部動脈中,造成骨骼掃描影像出現左前臂及手部的骨骼外局部顯影,即所謂的“手套現象”。本文將探討引起這類親骨放射性藥物在軟組織局部顯影的機轉與各種可能原因。